Women's Health asks researchers what people should know about a more potent GLP-1 medication that is still being tested in trials.
Recap by typeshit. Post by Women's Health on X.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
Researchers tested the combination in vivo and report lower peripheral immune activation and fewer inflammatory gene signatures in the central nervous system.
Investor Lupton argues Hims & Hers and NURS.V stand to benefit most if regulators move peptides back to category 1. This is his own view as an investor, not a regulatory decision.
Loading…